Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chie Emoto

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The Journal of Pharmacy and Pharmacology|August 28, 2002
Causative agent of vascular pain among photodegradation products of dacarbazineMariko Asahi, Ryo Matsushita, Masami Kawahara, et al.
Therapeutic Drug Monitoring|August 28, 2014
Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1Chie Emoto, Tsuyoshi Fukuda, Tomoyuki Mizuno, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2016
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell TransplantationPooja Khandelwal, Chie Emoto, Tsuyoshi Fukuda, et al.
Bone Marrow Transplantation|September 22, 2021
A prospective pilot study of a novel alemtuzumab target concentration intervention strategyDanielle E Arnold, Chie Emoto, Tsuyoshi Fukuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The Journal of Pharmacy and Pharmacology|August 28, 2002
Causative agent of vascular pain among photodegradation products of dacarbazineMariko Asahi, Ryo Matsushita, Masami Kawahara, et al.
Therapeutic Drug Monitoring|August 28, 2014
Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1Chie Emoto, Tsuyoshi Fukuda, Tomoyuki Mizuno, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2016
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell TransplantationPooja Khandelwal, Chie Emoto, Tsuyoshi Fukuda, et al.
Bone Marrow Transplantation|September 22, 2021
A prospective pilot study of a novel alemtuzumab target concentration intervention strategyDanielle E Arnold, Chie Emoto, Tsuyoshi Fukuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Pageof 5